

Disclosures

Personal Commercial (12)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Anumana	Research/Research Grants ‡ 1) Evaluation of AI ECG Algorithm to Detect LVEF < 40% 2) A Multicenter Study of Detection of Pulmonary Hypertension Based on Point-Of-Care 12-Lead ECG Data	Significant (>= \$5,000)	Noninvasive Imaging
Bracco Diagnostics	Consultant Fees/Honoraria	Modest (< \$5,000)	Noninvasive Imaging
EchoIQ	Other - Scientific Advisory Board	Modest (< \$5,000)	Noninvasive Imaging
Edwards Lifesciences	Consultant Fees/Honoraria	Significant (>= \$5,000)	Valvular Heart Disease
EVERSANA Lifesciences	Consultant Fees/Honoraria	Modest (< \$5,000)	General Cardiology
General Electric Healthcare	Consultant Fees/Honoraria	Modest (< \$5,000)	Noninvasive Imaging
HeartSciences	Other - Scientific Advisory Board	Significant (>= \$5,000)	Noninvasive Imaging
Pfizer	Data Safety Monitoring Board	Modest (< \$5,000)	General Cardiology
Philips Healthcare	Consultant Fees/Honoraria	Modest (< \$5,000)	Noninvasive Imaging
Philips Healthcare / DIA Analytics	Research/Research Grants ‡ Title: Retrospective Data Collection of Ultrasound Examinations that Include Contrast Enhanced Clips for the Development and Testing of Automated AI Based Tools	Significant (>= \$5,000)	Noninvasive Imaging
Ultromics	Other - Scientific Advisory Board	Modest (< \$5,000)	Noninvasive Imaging
Ultromics	Research/Research Grants ‡ EchoGoHF Device Evaluation	Significant (>= \$5,000)	Noninvasive Imaging

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (3)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
NIH/NHLBI	Research/Research Grants ‡ Chronic Renal Insufficiency and Silent Progression of Aortic Stenosis (CRISP-AS) Study	Significant (>= \$5,000)	Valvular Heart Disease
NIH/NHLBI ‡ none	Research/Research Grants ‡ 1K23HL144907	Significant (>= \$5,000)	Valvular Heart Disease
NIH/NIA ‡ none	Research/Research Grants	Significant (>= \$5,000)	Other

Clinical Trial Enroller (1)

Trial Name	Trial Sponsor	Trial Funding Source
EXPAND TAVR II	MEDTRONIC	

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (1)

Year	Case Title	Represented	Description	Compensation
<i>Self</i>				
2021	Atrial Fibrillation	Defendant	I provided medical advice to a defense attorney on a case of atrial fibrillation resulting in stroke	Modest (< \$5,000)

‡ Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 2/6/2024

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 2/6/2024

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 2/6/2024

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 2/6/2024

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.